Recent

% | $
Quotes you view appear here for quick access.

Tekmira Pharmaceuticals Corporation Message Board

  • kipk20122 kipk20122 Aug 14, 2014 8:57 AM Flag

    CEO was Extremely cautious on CC: Something is certainly goan happend next few days -

    They have the goods, but don't want to mess it up by rushing without haveing some sort or control and regulatory pass maround its use....

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wishful thinking...that's all you longs have left. Look at the facts as they are, not as you'd like them to be.

      • 4 Replies to intellectrader
      • This will validate the company’s technology and progress. Before Ebola, the play on this company was for it's hepatitis B results, which are due out soon enough. TKM-HBV is being developed as a multi-component RNAi therapeutic that targets multiple sites on the HBV genome. Because HBV is a viral infection of the liver, the TKM-HBV therapeutic will employ a liver-centric-LNP formulation that is more potent and has a broader therapeutic index than any LNP currently in clinical development. We anticipate completing the necessary preclinical work and expect to file an Investigational New Drug (IND) application in the second half of 2014. We plan to advance TKM-HBV into chronically infected HBV patients. 8 13 2014- __ The current outbreak underscores the critical need for an effective therapeutic agent to treat the Ebola virus,"said Dr. Mark J. Murray, Tekmira's President and CEO.__ "We remain sharply focused on our clinical programs and the key milestones to be reached by year end. Importantly, our Hepatitis B program continues to advance, with the goal of filing an IND, or equivalent, for our TKM-HBV program in the second half of 2014. _ _ TKM-PLK1 oncology platform, we expect to present Phase IIa interim data from our clinical trial with GI-NET and ACC patients before the end of this year, and we have begun enrollment in an additional Phase I/II trial targeting HCC patients," stated Dr. Murray._ __ For the second quarter ended June 30, 2014 we had cash, cash equivalents and investments of $129.5 million. The company has 22.1 million common shares issued and outstanding, and 24.6 million shares on a fully diluted basis.
        • The single ascending dose portion of the TKM-Ebola Phase I clinical trial has been successfully completed in healthy human volunteers. As per the protocol maximum tolerated dose (MTD) was established to be 0.3 mg/kg for healthy subjects without steroid premedication.
        • In July, we received notice from the U.S. Food & Drug Administration (FDA) that our TKM-Ebola program was on clinical hold. Subsequently, the company received written notice from the FDA modifying the clinical hold to a "partial clinical hold," allowing for the potential use of TKM-Ebola in individuals who have a confirmed or suspected Ebola infection. The company remains on clinical hold as it relates to the multiple-ascending dose portion of the Phase I clinical study in healthy volunteers with TKM-Ebola. The company expects this matter to be resolved by Q4 2014.
        • Our therapeutic, TKM-Ebola, is currently an unapproved agent and the regulatory framework to support its use in Africa has not yet been established. Given the severity of the situation, we are carefully evaluating options for use of our investigational drug within accepted clinical and regulatory protocols. This includes discussions with government agencies and NGO's, including the WHO, in various countries on the potential use of TKM-Ebola to treat Ebola virus infected individuals. There can be no assurance that an appropriate framework for the use of this product will be found. We will continue to provide updates as necessary when clinical and regulatory pathways become confirmed.
        • Within our TKM-PLK1 clinical trial targeting GI-NET and ACC patients, we saw an additional RECIST qualifying Partial Response (PR), defined as a greater than 30 percent reduction in target tumor lesions. This patient is continuing on therapy and has achieved a 44 percent reduction in their target tumor mass, located outside of the liver. Furthermore, scans of the target tumor lesions demonstrate signs of necrosis, indicative of anti-tumor activity.
        • We have initiated a Phase I/II clinical study of TKM-PLK1 in patients with Hepatocellular Carcinoma (HCC).
        • We intend to file an Investigational New Drug (IND) application, or equivalent, in the second half of 2014, in order to advance our TKM-HBV program into a Phase I clinical study, with initial data available in 2015.
        • We received an additional $1.5 million payment from Monsanto following completion of specified program developments

      • Those are the facts. You can misinterpret the context for the words "regulatory pathway" all you want. The fact is there has to be a plan for distribution and use of the limited inventory of the drug. TKMR said they are working on that plan by speaking directly with the WHO and African countries. This is what longs want. Stock would be spiking absent inartful way this was stated at the CC.

      • You basher do not have a clue as to what the company is , does or will be. You play the Technicals like surgeons chopping and making money with little moves. Others here are like the analyst that put a 26 dollar target on the stock before the EBOLA windfall. The Ebola run was nice but the company is so much more. GO@#$%^&* your self.

      • you no clue man......the facts is what deriving their decisions.....

    • "big brother is watching them" (FDA,US-GOV,WHO), they don't want to make a mistake !
      These "Bigs" says, what they have to tell you!

      GLTA

      Sentiment: Strong Buy

 
ABUS
4.69-0.13(-2.70%)May 3 3:59 PMEDT